Entities / Person
Mike Doustdar.
CEO of Novo Nordisk
- Reports this week
- 6
- Active events
- 2
- Connections
- 10
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Novo Nordisk CEO Mike Doustdar provided an outlook on the company's market potential.Well supported12 reports
-
The FDA has granted market exclusivity for certain drugs, while analysts are comparing Novo Nordisk's development phase to AI rollouts, amidst concerns over patent cliffs.Some support2 reports
Earlier this month
No events began in the chosen period. Widen it, or reset.
Around Mike Doustdar this week
News at the entities that move Mike Doustdar most-
Novo Nordisk StructuralBridgeBio and Novo Nordisk have both made filings under the KXCO Ontology.Moves Mike Doustdar
-
Reuters OperationalAndrii Biletskyi is reporting on military operations, including deploying UGVs and leading the Third Army Corps operations against Russian lines.Moves Mike Doustdar
-
Eli Lilly and Company Mentioned togetherExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Moves Mike Doustdar
Connections
The 3 strongest of 10, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Novo Nordisk Structural
Mike Doustdar serves as the president and CEO of Novo Nordisk, guiding its strategic direction.
-
Reuters Operational
Reuters utilizes Mike Doustdar as a source or expert regarding market trends in its reporting.
-
Eli Lilly and Company Mentioned together
Mike Doustdar publicly acknowledged the superiority of Eli Lilly's pill.